Nurix + Roche; Global BTK Degrader Collaboration

Summary Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology. What Happened Roche will co-develop and co-commercialize bexobrutideg, an oral degrader that eliminates BTK protein rather than inhibiting it. Deep Analysis The strategic significance is degradation…